Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

POC Blood Test Could Diagnose Brain Tumors Earlier

By LabMedica International staff writers
Posted on 04 Aug 2022

Image: A simple blood test for glioblastomas could mean earlier diagnosis (Photo courtesy of University of Bristol)

New research could lead to the development of a simple blood test for glioblastomas (GBMs), resulting in earlier diagnosis and more effective and personalized treatment options for the most common type of malignant brain cancer. The research involves the development of mathematical models to assess the current use of biomarkers in the detection of GBMs and how such biomarker-based strategies can be improved.

This research is part of a wider CRUX project led by the University of Bristol (Bristol, UK) to develop an affordable, point of care blood test to diagnose brain tumors. This cross-disciplinary project combines biomarker discovery, development of fluorescent nanoparticle and new testing techniques with computational modeling. In their recent study, mathematical models were developed and paired with experimental data. The researchers found that for the prospective GBM biomarker Glial fibrillary acidic protein (GFAP) lowering the current biomarker threshold could lead to earlier detection of GBMs. The team also used computational modeling to explore the impact of tumor characteristics and patient differences on detection and strategies for improvements.

“Our findings provide the basis for further clinical data on the impact of lowering the current detection threshold for the known biomarker, GFAP, to allow earlier detection of GBMs using blood tests,” said Dr. Johanna Blee, lead author and Research Associate in the University of Bristol’s Department of Engineering Mathematics. “With further experimental data, it may also be possible to quantify tumor and patient heterogeneities and incorporate errors into our models and predictions for blood levels for different tumors. We have also demonstrated how our models can be combined with other diagnostics such as scans to enhance clinical insight with a view to developing more personalized and effective treatments.”

“These mathematical models could be used to examine and compare new biomarkers and tests for brain tumors as they emerge. We are hopeful this research will ultimately aid the development of a simple blood test for brain tumors, enabling earlier and more detailed diagnoses,” added Dr. Blee.

Related Links:
University of Bristol